Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150031/S084

VERCISE DEEP BRAIN STIMULATION (DBS) SYSTEM

Boston Scientific Corp · Decision date Sep 13, 2026

MEDTECHLEDGER EXPLANATIONP150031/S084

What did the FDA approve?

The FDA's 13 September 2026 approval covers P150031/S084, a labeling-change supplement to Boston Scientific's Vercise Genus deep brain stimulation system. The reported purpose is to update MRI guidelines labeling so that the Vercise Cartesia X and HX 16-contact Directional Leads, 16-contact Lead Extensions, and 8x2-contact Lead Extensions are included in the configurations approved for 1.5T MRI scans. The filing used the normal 180-day track, with the stated reason listed as labeling change affecting indications, instructions, shelf life or tradename.

Because the identifier is a supplement to P150031, it modifies labeling for that existing approval rather than constituting a new approval of the whole system. The statement does not specify the revised warning wording, conditions of scanning, or any clinical data, so safety or effectiveness beyond the listed 1.5T configurations cannot be concluded from this record alone.

The source does not describe the original 2020-era PMA scope in detail. What is absent is the specific labeling text changed, the evidence reviewed, and any separate indication change; only the MRI configuration scope is identified.

FDA approval order statement

approval for MRI guidelines labeling updates to include the Vercise Cartesia X and HX 16-contact Directional Leads, 16-contact Lead Extensions, and 8x2-contact Lead extensions of the Vercise Genus DBS System to the configurations approved for 1.5T MRI scans.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Neurology
Decision date
Sep 13, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P150031/S084
Regulatory pathway
PMA supplement
Product code
NHL
Decision code
APPR
Decision date
Sep 13, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, electrical, implanted, for parkinsonian symptoms.

Product code
NHL
FDA device class
3

For the original device and its historical approval scope, see PMA P150031. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P150031 · Original PMA

    VERCISE DEEP BRAIN STIMULATION (DBS)SYSTEM

  2. P150031/S084 received

    Application receipt date recorded by FDA.

  3. P150031/S084 · FDA decision

    Normal 180 Day Track

  4. P150031/S098 · Related supplement

    Vercise Genus DBS Systems; Vercise Gevia DBS Systems

  5. P150031/S102 · Related supplement

    Vercise Deep Brain Stimulation (DBS) Systems

Timeline entries are records held by MedtechLedger for P150031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150031

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA approvalDec 8, 2017FDA
Boston Scientific CorpPMA supplementSep 22, 2026FDA
Boston Scientific CorpPMA supplementOct 15, 2026FDA
Boston Scientific CorpPMA supplementOct 30, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
25155 Rye Canyon Loop, Valencia, CA, 91355

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records